Quantification of the Therapeutic Antibody Ocrelizumab in Mouse Brain Interstitial Fluid Using Cerebral Open Flow Microperfusion and Simultaneous Monitoring of the Blood–Brain Barrier Integrity

The increasing relevance of improved therapeutic monoclonal antibodies (mAbs) to treat neurodegenerative diseases has strengthened the need to reliably measure their brain pharmacokinetic (PK) profiles. The aim of this study was, therefore, to absolutely quantify the therapeutic antibody ocrelizumab...

Descrición completa

Detalles Bibliográficos

Principais autores:	Thomas Altendorfer-Kroath, Joanna Hummer, Denise Kollmann, Beate Boulgaropoulos, Reingard Raml, Thomas Birngruber
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2023-07-01
Series:	Pharmaceutics
Assuntos:	cerebral open flow microperfusion cOFM blood–brain barrier BBB therapeutic antibody absolute quantification
Acceso en liña:	https://www.mdpi.com/1999-4923/15/7/1880
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!